Dr. Byrne's comment is not accurate. IM naltrexone did not "increase the likelihood of recovery from opioid dependence". It did lead to a relative decrease in the use of illicit opiates, but only during the first 6 months of treatment. The study's other major finding was that "prevention of opioid use by extended-release naltrexone did not persist through follow-up at week 52 and week 78, approximately 6 months and 12 months, respectively, after the treatment phase had ended. In addition, we did not detect a benefit of extended-release naltrexone on several important secondary outcomes, including rates of cocaine, heavy alcohol, and injection-drug use. Rates of self-reported reincarceration and days of incarceration through week 27 were also not significantly lower in the extended-release naltrexone group than in the usual-treatment group."
There are additional concerns here: this was an open-label study with significant industry funding. Several of the principal authors have significant conflicts of interest (details are provided online).
But the real elephant in this room is the shameful lack of access to long-term medication assisted treatment that has been shown conclusively, in multiple studies, to reduce overdose deaths, increase treatment adherence, and decrease recidivism. IM naltrexone constitutes a sort of poor man's opioid dependence treatment that doesn't achieve any of those crucial objectives.